Reported about 12 hours ago
Eli Lilly's stock has surged over the past year, largely driven by its leading role in the booming weight loss drug market. Recent news that the FDA has removed Lilly's tirzepatide from its shortage list could potentially unlock billions in revenue since this allows Lilly to address high customer demand directly, shifting sales away from compounding pharmacies that had been filling the gap. Additionally, Lilly's innovative pricing strategy with single-dose vials aims to attract more customers, further solidifying its growth potential in the face of competition.
Source: YAHOO